Respiratory syncytial virus bronchiolitis.
Respiratory syncytial virus (RSV) bronchiolitis is associated with the clinical signs and symptoms of small airway obstruction. A major public health problem throughout the world, this condition is responsible for significant morbidity and mortality. Management is primarily preventive, through strict hand washing, avoidance of exposure during the respiratory illness season and intravenously administered prophylactic anti-RSV Immune globulin, especially in selected small infants with underlying cardiopulmonary disease. Supportive measures, including fluid hydration, good nutrition, aerosolized bronchodilators and steroids, may be helpful. Ribavirin may be useful in severely ill children or those with underlying cardiopulmonary disease. A significant number of patients have recurrent episodes of bronchiolitis and wheezing, and may develop asthma later in life. Avoidance of exposure to tobacco smoke, cold air and air pollutants is also beneficial to long-term recovery from RSV bronchiolitis. A number of vaccines to prevent this infection are currently being studied.
Jeng
M J
MJ
Department of Pediatrics, National Yang-Ming University, Taipei, Taiwan.
Lemen
R J
RJ
D001988:Bronchiolitis / Q000175:diagnosis / Q000517:prevention & control / Q000628:therapy / Q000821:virology*; D002648:Child; D002675:Child, Preschool; D006760:Hospitalization; D006801:Humans; D007223:Infant; D011379:Prognosis; D012121:Respiration, Artificial; D018357:Respiratory Syncytial Virus Infections / Q000175:diagnosis / Q000517:prevention & control / Q000628:therapy